Analysis of Somatostatin-Receptor 2A (SSTR2A) Immunohistochemistry, RT-qPCR and In-Vivo- PET/CT Data in Patients with Pancreatic Neuroendocrine Neoplasm


Introduction: Ga-68 somatostatin receptor (SSTR) PET/CT is one of the most sensitive imaging methods for pancreatic neuroendocrine tumors.

Aim(s): We analyzed if the receptor density predicted by the semi-quantitative parameters generated from the static PET/CT (standard uptake values – SUVmax / SUVmean) correlate with ex-vivo SSTR2A immunohistochemistry (IHC) and RT-qPCR gene expression data.

Materials and methods: Twenty-three pancreatic neuroendocrine tumor specimens (14 primary tumors, nine metastases) of 15 patients were evaluated. PET/CT was performed preoperatively in all patients. SSTR2A and Ki-67 expression was quantified immunohistochemically using the Immunoreactive Score (IRS), according to Remmele and Stegner as well as by means of RT-qPCR.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kaemmerer D, Wirtz R, Fischer E, Hommann M, Sänger J,

Keywords: molecular imaging, somatostatin receptor, pancreatic tumor,

To read the full abstract, please log into your ENETS Member account.